.0001 to .0009 PICKS ONLY

[Rider76]

$RCHA News!

Rich Pharmaceuticals, Inc. Announces Quarterly Milestones
BEVERLY HILLS, Calif., Sept. 27, 2016 /PRNewswire/ -- Rich Pharmaceuticals, Inc. (OTC Markets: RCHA) ("Rich Pharmaceuticals" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology, announced today several of the milestones it had reached during the past quarter, and those that it intends to pursue in the upcoming quarters.

Rich Pharmaceuticals has:

Received clearance from the U.S. Food and Drug Administration (FDA) to commence its Phase 1/2 clinical trials for the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients.
Submitted full clinical package to a major Southeast US University Medical school to conduct the AML study. The package is currently in review with the University's Scientific Review Board (SRB) and Institutional Review Board (IRB).
Submitted full clinical package to a major Thailand medical center to conduct the AML study. The package is currently in review with the Center's Scientific Review Board (SRB) and Institutional Review Board (IRB) currently, in review with SRB and IRB.
Retained the services of an Asian Contract Research Organization ("CRO"), CMIC ASIA-PACIFIC, PTE. LTD. ("CMIC"), to run Rich's upcoming Phase 1/2 clinical for the treatment of AML and MDS patients in connection with Asian Phase 1/2 clinical trials. CMIC is considered to be one of Asia's top CRO's for running clinical oncology studies.
A protocol for Hodgkin's Lymphoma is in final review and being prepared for submission to the FDA using the company's existing Investigational New Drug (IND).
In the upcoming quarters, and subject to receiving sufficient capital, Rich intends to:

Receive IRB approval from the US University to commence the Phase 1/2 study in the US.
Receive IRB approval from the Thailand medical to commence the Phase 1/2 study in the Thailand.
Enroll the first patient in US and Thailand.
Submit the Hodgkin's Lymphoma protocol to the FDA
Submit Hodgkin's Lymphoma clinical package to the medical Universities and medical centers in the last quarter of 2016 for SRB and IRB review.

http://www.prnewswire.com/news-releases/rich-pharmaceuticals-inc-announces-quarterly-milestones-300334673.html